873055-57-3

Usage

Uses

Used in Chemical Synthesis:
Phenol, 2,4-bis(1,1-diMethylethyl)-5-nitrois used as an intermediate in the chemical synthesis industry for the production of various compounds. Its unique structure allows it to be a versatile building block in the creation of pharmaceuticals and agricultural products, contributing to the development of new and improved formulations.
Used in Corrosion Inhibition:
In the industrial sector, Phenol, 2,4-bis(1,1-diMethylethyl)-5-nitrois utilized as a corrosion inhibitor. Its ability to protect metal surfaces from corrosion is valuable in various applications, including the maintenance of pipelines, storage tanks, and other metal structures, thereby extending their service life and reducing maintenance costs.
Used in Dyes and Pigments Production:
Phenol, 2,4-bis(1,1-diMethylethyl)-5-nitroalso serves as an intermediate in the production of dyes and pigments. Its chemical properties make it suitable for the synthesis of colorants used in a wide range of industries, such as textiles, plastics, and printing inks, enhancing the color quality and performance of the final products.

Upstream product

• 873055-54-0 carbonic acid 2,4-di-tert-butyl-phenyl ester methyl ester 
• 96-76-4 2,4-di-tert-Butylphenol 
• 873055-55-1 carbonic acid 2,4-di(tert-butyl)-5-nitrophenyl ester methyl ester 
• 873055-56-2 carbonic acid 2,4-di(tert-butyl)-6-nitrophenyl ester methyl ester 

Downstream Products

• 873055-58-4 5-amino-2-4-di-tert-butyl-phenol 
• 873054-44-5 ivacaftor 
• 1182822-31-6 5-amino-2,4-di-tert-butylphenyl methyl carbonate 
• 873055-55-1 carbonic acid 2,4-di(tert-butyl)-5-nitrophenyl ester methyl ester 
• 1085-21-8 2,4-di-tert-butyl-6-(N-methylamino)phenol 

Relevant academic research and scientific papers

COMPOUND FOR TREATING CYSTIC FIBROSIS

Provided herein is a compound represented by Formula I: or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. Also provided are pharmaceutical compositions comprising the compound noted above, in combination with a pharmaceutically acceptable excipient.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

This application describes methods of treating cystic fibrosis comprising administering Compound I:, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the foregoing.

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809

The 1,2,3-triazole has been successfully utilized as an amide bioisostere in multiple therapeutic contexts. Based on this precedent, triazole analogues derived from VX-809 and VX-770, prominent amide-containing modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), were synthesized and evaluated for CFTR modulation. Triazole 11, derived from VX-809, displayed markedly reduced efficacy in F508del-CFTR correction in cellular TECC assays in comparison to VX-809. Surprisingly, triazole analogues derived from potentiator VX-770 displayed no potentiation of F508del, G551D, or WT-CFTR in cellular Ussing chamber assays. However, patch clamp analysis revealed that triazole 60 potentiates WT-CFTR similarly to VX-770. The efficacy of 60 in the cell-free patch clamp experiment suggests that the loss of activity in the cellular assay could be due to the inability of VX-770 triazole derivatives to reach the CFTR binding site. Moreover, in addition to the negative impact on biological activity, triazoles in both structural classes displayed decreased metabolic stability in human microsomes relative to the analogous amides. In contrast to the many studies that demonstrate the advantages of using the 1,2,3-triazole, these findings highlight the negative impacts that can arise from replacement of the amide with the triazole and suggest that caution is warranted when considering use of the 1,2,3-triazole as an amide bioisostere.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

Methods of treating cystic fibrosis comprising administering at least Compound (I) of the formula. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound (I).

CRYSTALLINE FORMS OF MODULATORS OF CFTR

Crystalline Forms of Compound (I); crystalline Forms of Compound (II) and crystalline forms of pharmaceutically acceptable salts of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS

A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS

Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.

COMPOSITIONS FOR TREATING CYSTIC FIBROSIS

A single tablet comprising Compound I:. Methods of treating cystic fibrosis comprising administering one or more of such single tablets to a patient.